Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label rizatriptan safety study in adolescents with migraine
NL-OMON34736Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rizatriptan in migraine (2 arms), sponsored by Merck & Co. Primary endpoint: Long-term safety and tolerability of rizatriptan. Started Mar 2010; status: active, not recruiting.
02
Drugs
rizatriptan
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON34736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34736.